Dr. Danilo Verge is a Biotech and Pharma Medical Executive with more than 20 years of experience in the fields of metabolism, obesity, and renal and cardiovascular disease, based in the United States and various European countries. Dr. Verge has most recently served as the Head of Patient Safety and Medical Affairs at Zealand Pharma, based in Copenhagen, Denmark. Previous roles include Vice President of Global Medical Affairs for CV, Renal and Metabolic diseases at AstraZeneca, based in Gaithersburg, MD and Gothenburg, Sweden: and Vice President of Medical Affairs at Novo Nordisk US, based in Princeton, NJ. He previously held international positions within Novo Nordisk (headquarters in Copenhagen, regional European office in Zurich and in the Spanish affiliate in Madrid) and has been involved in the development of many of its antidiabetic compounds, including insulin analogs and liraglutide.
Dr. Verge obtained his Bachelor of Science at St. Lawrence University in Canton, New York, and his medical degree at the University of Buenos Aires, Argentina. He also holds a Master of Business Administration degree from SIMI (now part of Copenhagen Business School) in Copenhagen.
Dr. Verge is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has published a review on cardiovascular aspects of GLP-1R agonists, two reviews in the area of insulin analogs and is an occasional contributor to Pharmaceutical Marketing Europe, a specialized industry magazine.